Related Experiment Video
Updated: Mar 28, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
1.1K
Multi-Modal Fusion and Longitudinal Analysis for Alzheimer's Disease Classification Using Deep Learning.
Shakhnoza Muksimova1, Sabina Umirzakova1, Jushkin Baltayev2
1Department of Computer Engineering, Gachon University, Sujeong-gu, Seongnam-si 461-701, Gyeonggi-do, Republic of Korea.
Diagnostics (Basel, Switzerland)
|March 28, 2025
Summary
FusionNet enhances Alzheimer's disease (AD) diagnosis by integrating multi-modal imaging data. This advanced framework achieves high accuracy, aiding early detection and personalized treatment strategies for AD.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Medical Diagnostics
Background:
- Alzheimer's disease (AD) diagnosis presents significant challenges.
- Current diagnostic methods often lack comprehensive data integration.
- There is a need for advanced tools to improve AD classification and monitoring.
Purpose of the Study:
- To introduce FusionNet, a novel framework for enhanced AD classification.
- To integrate multi-modal and longitudinal imaging data for improved diagnostic accuracy.
- To enable early detection and continuous monitoring of Alzheimer's disease.
Main Methods:
- FusionNet synthesizes data from MRI, PET, and CT scans.
- Utilizes machine learning: GANs for data augmentation, lightweight neural networks, and deep metric learning.
- Combines cross-sectional and temporal data with specialized feature extraction and attention mechanisms.
Main Results:
- FusionNet demonstrates superior performance in AD classification.
- Achieved an accuracy of 94%.
- Reported precision of 92% and recall of 93%.
Conclusions:
- FusionNet shows potential as a reliable diagnostic tool for Alzheimer's disease.
- Facilitates early intervention and personalized treatment strategies.
- Offers insights into AD progression, supporting patient care and research.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

